Herantis Pharma

HER-096 clears Phase Ib, eyes Phase II

Herantis Pharma reported positive top-line results from the second part of its Phase Ib trial, evaluating lead candidate HER-096 in Parkinson's disease (PD) patients, meeting both the primary and secondary endpoints. Both 200mg and 300mg twice-weekly doses (administered for four weeks) were shown to be safe, well tolerated and achieved the predicted cerebrospinal fluid (CSF) exposure, confirming effective blood-brain barrier (BBB) penetration. We look forward to the full dataset and biomarker data to be released before end FY25 and believe that these top-line results provide pharmacological rationale for HER-096 to advance to Phase II efficacy studies. The 300mg twice-weekly dose has been deemed suitable for the Phase II trial in early-stage PD patients, expected to commence in 2026, potentially under a partnering agreement.

After demonstrating a favourable safety and pharmacological profile in part one of the Phase Ib study (in elderly, healthy volunteers; n=8; 300mg single dose), part two was designed to test HER-096 in PD patients with repeated subcutaneous doses. This was a randomised, double-blind part of the study designed to assess safety and biomarkers with multiple doses of HER-096 in PD patients (12 each at 200mg and 300mg twice weekly, randomised 2:1 between the treatment and placebo arms).

The study met both its primary endpoints (safety and tolerability) and secondary objectives (pharmacokinetics), reporting mostly mild adverse events (AEs) in the treatment arms (one serious AE reported in the placebo cohort) and pharmacologically active drug concentration in CSF, confirming strong BBB penetration. By targeting the deregulated unfolded protein response pathway signalling, HER-096 is designed to address key mechanisms underlying PD progression (rather than just symptom control), offering disease-modifying potential, a significant unmet need in PD. We believe that initial confirmation of effective brain penetration by the compound, a historical hurdle with its predecessor cerebral dopamine neurotrophic factor (CDNF), represents a meaningful milestone supporting its translational potential.

The Phase Ib trial was not designed or sufficiently powered to test efficacy (stable motor scores were reported across both treatment and placebo arms, indicative of the small patient population and short treatment duration) and we look forward to the biomarker data (to be reported before end FY25) for any initial symptoms of biological activity. We expect the company to use this data to refine the Phase II design prior to trial initiation in FY26. In terms of dosing, 300mg twice weekly has been deemed suitable for the Phase II trial by management. While this Phase Ib trial was funded by the Michael J Fox Foundation and Parkinson's UK, we expect Herantis to seek a partnering agreement for the upcoming Phase II study. Herantis had a gross cash balance of €4.6m at end H125, with a runway into Q226, as per management guidance.

Historical financials

Year end	Revenue (€m)	PBT (€m)	EPS (€)	DPS (€)	P/E (x)	Yield (%)
12/22	0.0	(9.3)	(0.64)	0.00	N/A	N/A
12/23	0.0	0.3	0.02	0.00	N/A	N/A
12/24	0.0	(4.9)	(0.24)	0.00	N/A	N/A

Source: LSEG Data & Analytics

Healthcare

8 October 2025

Price	**€2.72**
Market cap	**€60m**

Share price performance



Share details

Code	HRTIS
Listing	HEL
Shares in issue	24.1m
Gross cash/equivalents at 30 June 2025	€4.6m

Business description

Herantis Pharma is a clinical-stage biotechnology company based in Finland. It is focused on developing disease-modifying therapies to stop or reverse the progression of neurodegenerative diseases. Lead candidate HER-096 is a peptide mimic of CDNF protein, and has successfully completed Phase Ib for Parkinson's disease.

Bull points

- Lead candidate has a novel mechanism of action and has shown promising early pharmacokinetics data in humans.
- Sizeable commercial opportunity for an effective PD treatment with disease-modifying properties.
- External validation received via funding from recognised organisations, including the European Innovation Council, the MJFF and Parkinson's UK.

Bear points

- Extended time to market and reliant on external funding to progress the development of HER-096.
- Typical regulatory, development and funding risks associated with the early stages of drug development.
- With its reliance on a single programme, Herantis is exposed to binary event risks.

Analysts

Jyoti Prakash, CFA +44 (0)20 3077 5700
Arron Aatkar, PhD +44 (0)20 3077 5700

healthcare@edisongroup.com
Edison profile page

General disclaimer and copyright

This report has been commissioned by Herantis Pharma and prepared and issued by Edison, in consideration of a fee payable by Herantis Pharma. Edison Investment Research standard fees are £60,000 pa for the production and broad dissemination of a detailed note (Outlook) following by regular (typically quarterly) update notes. Fees are paid upfront in cash without recourse. Edison may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services.

Accuracy of content: All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained in this report represent those of the research department of Edison at the time of publication. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.

Exclusion of Liability: To the fullest extent allowed by law, Edison shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out or in connection with the access to, use of or reliance on any information contained on this note.

No personalised advice: The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The securities described in the report may not be eligible for sale in all jurisdictions or to certain categories of investors.

Investment in securities mentioned: Edison has a restrictive policy relating to personal dealing and conflicts of interest. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report, subject to Edison's policies on personal dealing and conflicts of interest.

Australia

Edison Investment Research Pty Ltd (Edison AU) is the Australian subsidiary of Edison. Edison AU is a Corporate Authorised Representative (1252501) of Crown Wealth Group Pty Ltd who holds an Australian Financial Services Licence (Number: 494274). This research is issued in Australia by Edison AU and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. Any advice given by Edison AU is general advice only and does not take into account your personal circumstances, needs or objectives. You should, before acting on this advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Product Disclosure Statement or like instrument.

New Zealand

The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (i.e. without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision.

United Kingdom

This document is prepared and provided by Edison for information purposes only and should not be construed as an offer or sol icitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.

This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "FPO") (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document.

This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.

United States

Edison relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This report is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Edison does not offer or provide personal advice and the research provided is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.

London | New York | Frankfurt
20 Red Lion Street
London, WC1R 4PS
United Kingdom